Contineum Therapeutics

Currently Hiring

About the company

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need.

Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials.

PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain.

PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder.

For more information, please visit www.contineum-tx.com.

Open jobs

Browse and apply for open jobs at Contineum Therapeutics.

3 jobs found